{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:45:17Z","timestamp":1793684717942,"version":"4.5.1"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) has been widely adopted, yet clinical use and outcomes are unknown. Furthermore, optimal therapy is uncertain due to lack of direct comparison of androgen receptor pathway inhibitors (ARPIs) and docetaxel in high-volume disease.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the use of combination therapy and its association with overall survival among patients with mHSPC and to compare ARPIs vs docetaxel doublet therapy by volume of disease.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cross-sectional study was conducted in the US Veterans Health Administration among 6216 US veterans with de novo mHSPC from January 1, 2013, to December 31, 2022, treated with androgen deprivation therapy (ADT) within 3 months of diagnosis. Treatments for mHSPC were collected within 4 months of ADT. Volume of disease was assessed from radiology report review. Data were analyzed from July 2023 to October 2024.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Overall survival (OS) and clinical progression-free survival (PFS), indicated by time to castration resistance or death.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 6216 male veterans with mHSPC (mean [SD] age, 73.9 [9.7] years), use of combination therapy increased from 344 of 637 veterans (54.0%) in 2020 to 465 of 737 veterans (63.1%) in 2022. Among 4106 veterans treated from 2017 to 2022, combination therapy was associated with longer OS (40.3 [95% CI, 38.0-42.1] months vs 33.0 [95% CI, 31.2-35.1] months; hazard ratio [HR], 0.80 [95% CI, 0.74-0.87]) and was used more frequently among younger veterans with fewer comorbidities. Among 1174 veterans with high-volume mHSPC, there was no difference in OS between ARPIs and docetaxel (32.3 [95% CI, 29.5-35.3] months vs 34.7 [95% CI, 31.7-37.1] months; HR, 1.06 [95% CI, 0.91-1.23]); however, ARPIs were associated with longer PFS (18.7 [95% CI, 17.1-20.9] months vs 16.0 [95% CI, 14.0-17.7] months; HR, 0.80 [95% CI, 0.70-0.91]; P<\/jats:italic>\u2009=\u2009.001). In a multivariable model of high-volume mHSPC, there was no difference in OS between ARPIs and docetaxel (adjusted HR, 0.89 [95% CI, 0.76-1.05]). Among 366 veterans with low-volume mHSPC, there was no difference in OS between ARPIs and docetaxel (68.4 [95% CI, 52.6 months to not reached] months vs 55.3 [95% CI, 41.7-78.9] months; HR, 0.81 [95% CI, 0.58-1.13]), but ARPIs were associated with longer PFS (39.7 [95% CI, 34.3-52.9] months vs 24.0 [95% CI, 20.3-32.9] months; HR, 0.57 [95% CI, 0.43-0.76]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cross-sectional study of veterans with de novo mHSPC, use of combination therapies increased over time and were associated with longer survival compared with ADT monotherapy. In both high- and low-volume mHSPC, no differences in OS were observed between ARPI and docetaxel combinations; however, ARPIs had longer PFS. Future research into the role of docetaxel is needed to elucidate the benefit of chemotherapy in mHSPC.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.9433","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T15:01:03Z","timestamp":1746716463000},"page":"e259433","source":"Crossref","is-referenced-by-count":20,"title":["Treatment Patterns and Survival Among Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Martin W.","family":"Schoen","sequence":"first","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Doherty","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eaton","sequence":"additional","affiliation":[{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira","family":"Khan","sequence":"additional","affiliation":[{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"},{"name":"Division of Public Health Sciences, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Candelieri","sequence":"additional","affiliation":[{"name":"Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Fedele","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Baxi","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Wynveen","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carley","family":"Pickett","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jackson","family":"Wilson","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Stackable","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Ingram","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishny","family":"Karunanandaa","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Agarwal","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Rajasekhar","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forest","family":"Riekhof","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Govindan","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Cheranda","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine, St Louis, Missouri"},{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Knoche","sequence":"additional","affiliation":[{"name":"Veterans Affairs St Louis Healthcare System, St Louis, Missouri"},{"name":"Division of Public Health Sciences, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Missouri"},{"name":"Division of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth D.","family":"Etzioni","sequence":"additional","affiliation":[{"name":"Fred Hutch Cancer Center, Seattle, Washington"},{"name":"Department of Biostatistics, University of Washington School of Public Health, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Bruce","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Fred Hutch Cancer Center, Seattle, Washington"},{"name":"Division of Hematology and Oncology, University of Washington School of Medicine, Seattle"},{"name":"Veterans Affairs Puget Sound Health Care System, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"10437","key":"zoi250340r1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases.","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"zoi250340r2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"zoi250340r3","doi-asserted-by":"publisher","first-page":"LBA2","DOI":"10.1200\/jco.2014.32.18_suppl.lba2","article-title":"Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial.","volume":"32","author":"Sweeney","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10024","key":"zoi250340r4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"zoi250340r5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi250340r6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy.","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"32","key":"zoi250340r7","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi250340r8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer.","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250340r9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6973","article-title":"Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi250340r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.1970","article-title":"Survival in patients with de novo metastatic prostate cancer.","volume":"7","author":"Schoen","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi250340r11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnci\/djad020","article-title":"Changes in survival in de novo metastatic cancer in an era of new medicines.","volume":"115","author":"Luyendijk","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi250340r12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euo.2023.05.002","article-title":"Does research from clinical trials in metastatic hormone-sensitive prostate cancer treatment translate into access to treatments for patients in the \u201creal world\u201d? a systematic review.","volume":"7","author":"Dodkins","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"zoi250340r13","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis.","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi250340r14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41391-022-00588-5","article-title":"Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases.","volume":"26","author":"Schoen","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"zoi250340r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101520","article-title":"Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer.","volume":"14","author":"Deol","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"zoi250340r16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/oncolo\/oyad047","article-title":"The management of metastatic castrate-sensitive prostate cancer: from guidelines to real-world practice.","volume":"28","author":"Gebrael","year":"2023","journal-title":"Oncologist"},{"issue":"9","key":"zoi250340r17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/oncolo\/oyad045","article-title":"Real-world treatment trends among patients with metastatic castration-sensitive prostate cancer: results from an international study.","volume":"28","author":"Barata","year":"2023","journal-title":"Oncologist"},{"issue":"6","key":"zoi250340r18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1200\/JCO.2023.41.6_suppl.85","article-title":"First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.","volume":"41","author":"Mucci","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi250340r19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"issue":"20","key":"zoi250340r20","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial.","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi250340r21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis.","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10336","key":"zoi250340r22","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2?\u00d7?2 factorial design.","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"20","key":"zoi250340r23","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"zoi250340r25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi250340r26","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00085","article-title":"Development and validation of a tool to identify patients diagnosed with castration-resistant prostate cancer.","volume":"7","author":"Candelieri-Surette","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"11","key":"zoi250340r27","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"4","key":"zoi250340r28","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.euo.2023.11.023","article-title":"Adaption and national validation of a tool for predicting mortality from other causes among men with nonmetastatic prostate cancer.","volume":"7","author":"Justice","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"zoi250340r29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00345-024-05388-1","article-title":"Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer.","volume":"43","author":"Wenzel","year":"2024","journal-title":"World J Urol"},{"issue":"5","key":"zoi250340r30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.2025.43.5_suppl.20","article-title":"Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).","volume":"43","author":"Fisher","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi250340r31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review.","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"zoi250340r24","author":"Shelton"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2833712\/schoen_2025_oi_250340_1746112628.74982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T15:01:04Z","timestamp":1746716464000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2833712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.9433","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}